Instadose Pharma Corp Stock Shares Owned By Insiders
| INSD Stock | USD 0 0.00 0.00% |
Instadose Pharma Corp fundamentals help investors to digest information that contributes to Instadose Pharma's financial success or failures. It also enables traders to predict the movement of Instadose Stock. The fundamental analysis module provides a way to measure Instadose Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Instadose Pharma stock.
Instadose | Shares Owned By Insiders |
Instadose Pharma Corp Company Shares Owned By Insiders Analysis
Instadose Pharma's Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Instadose Pharma Shares Owned By Insiders | 34.03 % |
Most of Instadose Pharma's fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Instadose Pharma Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Instadose Shares Owned By Insiders Driver Correlations
Understanding the fundamental principles of building solid financial models for Instadose Pharma is extremely important. It helps to project a fair market value of Instadose Stock properly, considering its historical fundamentals such as Shares Owned By Insiders. Since Instadose Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Instadose Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Instadose Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 34.03% of Instadose Pharma Corp are shares owned by insiders. This is 124.18% higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The shares owned by insiders for all United States stocks is notably lower than that of the firm.
Instadose Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Instadose Pharma's direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Instadose Pharma could also be used in its relative valuation, which is a method of valuing Instadose Pharma by comparing valuation metrics of similar companies.Instadose Pharma is currently under evaluation in shares owned by insiders category among its peers.
Instadose Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Instadose Pharma from analyzing Instadose Pharma's financial statements. These drivers represent accounts that assess Instadose Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Instadose Pharma's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Enterprise Value | 7.4M | 7.4M | 7.4M | 1.8B | 1.7B | 1.7B |
Fund Asset Allocation for Instadose Pharma
The fund invests 99.58% of asset under management in tradable equity instruments, with the rest of investments concentrated in various types of exotic instruments.Asset allocation divides Instadose Pharma's investment portfolio among different asset categories to balance risk and reward by investing in a diversified mix of instruments that align with the investor's goals, risk tolerance, and time horizon. Mutual funds, which pool money from multiple investors to buy a diversified portfolio of securities, use asset allocation strategies to manage the risk and return of their portfolios.
Mutual funds allocate their assets by investing in a diversified portfolio of securities, such as stocks, bonds, cryptocurrencies and cash. The specific mix of these securities is determined by the fund's investment objective and strategy. For example, a stock mutual fund may invest primarily in equities, while a bond mutual fund may invest mainly in fixed-income securities. The fund's manager, responsible for making investment decisions, will buy and sell securities in the fund's portfolio as market conditions and the fund's objectives change.
Instadose Fundamentals
| Return On Asset | -694.06 | ||||
| Current Valuation | 757.11 K | ||||
| Shares Outstanding | 531.93 M | ||||
| Shares Owned By Insiders | 34.03 % | ||||
| Price To Book | 0.02 X | ||||
| EBITDA | (462.02 K) | ||||
| Net Income | 462.02 K | ||||
| Cash And Equivalents | 5.33 K | ||||
| Total Debt | 162.3 K | ||||
| Debt To Equity | 0.01 % | ||||
| Book Value Per Share | 0.07 X | ||||
| Cash Flow From Operations | (65) | ||||
| Earnings Per Share | (0.01) X | ||||
| Beta | -945.3 | ||||
| Market Capitalization | 585.13 K | ||||
| Retained Earnings | (568.38 K) | ||||
| Working Capital | (162.3 K) | ||||
| Year To Date Return | 9.44 % | ||||
| One Year Return | 9.44 % | ||||
| Equity Positions Weight | 99.58 % |
About Instadose Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Instadose Pharma Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Instadose Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Instadose Pharma Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Instadose Pharma Corp is a strong investment it is important to analyze Instadose Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Instadose Pharma's future performance. For an informed investment choice regarding Instadose Stock, refer to the following important reports:Check out Instadose Pharma Piotroski F Score and Instadose Pharma Altman Z Score analysis. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Instadose Pharma. If investors know Instadose will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Instadose Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.01) | Return On Assets (694.06) |
The market value of Instadose Pharma Corp is measured differently than its book value, which is the value of Instadose that is recorded on the company's balance sheet. Investors also form their own opinion of Instadose Pharma's value that differs from its market value or its book value, called intrinsic value, which is Instadose Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Instadose Pharma's market value can be influenced by many factors that don't directly affect Instadose Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Instadose Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Instadose Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Instadose Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.